Jean-Baptiste Rey1, Nicolas Jovenin2, Pierre Kreit3, Jérôme Sicard4, Damien Parent5, Dominique Hettler6, Philippe Nguyen7, Jean-Luc Ducrocq8. 1. Institut de Cancérologie Jean Godinot, Département de Pharmacie, France Université de Reims Champagne-Ardenne, Faculté de Pharmacie - Laboratoire EA4691, France jean-baptiste.rey@reims.unicancer.fr. 2. Réseau Régional de Cancérologie Champagne-Ardenne, France. 3. URPS Pharmaciens Champagne-Ardenne, France. 4. Pharmacie Principale, Châlons en Champagne, France. 5. Institut de Cancérologie Jean Godinot, Département de Pharmacie, France. 6. CHU de Reims, Pharmacie, France ARS Champagne-Ardenne, OMEDIT, Châlons en Champagne, France. 7. CHU de Reims, Laboratoire d'Hématologie, France Université de Champagne-Ardenne, Faculté de Médecine, France. 8. Leo Pharma, Medical Affairs, Voisins le Bretonneux, France.
Abstract
INTRODUCTION: Venous thromboembolism is common in cancer. Low-molecular weight heparins are recommended for prolonged treatment (3-6 months or more if the cancer is active) and prevention of recurrence of venous thromboembolism in cancer. Community pharmacists are often faced with questions from patients. The main objective of this study was to describe the organization, practices and knowledge of pharmacists in care of venous thromboembolism in cancer patients. METHODS: A descriptive survey was conducted electronically in October and November 2013 with pharmacists in the Champagne-Ardenne region. The questionnaire collected data on the general organization of the pharmacy, management of outpatients with cancer and thrombosis, and the level of knowledge regarding recommendations on the management of thrombosis in patients with cancer. RESULTS: The participation rate was 31.6%. In 93% of cases, pharmacists had no particular expertise in oncology and/or supportive care. In addition, 96% did not know the existence of recommendations for "thrombosis in cancer." Finally, 49% gave the correct answer to the case report (low-molecular weight heparins). CONCLUSION: Training sessions on the management of venous thromboembolism in cancer are currently available to pharmacists in the region. A new assessment of knowledge will be performed at the end of the year 2014. This regional experience is now extended to a national level (all French regions).
INTRODUCTION:Venous thromboembolism is common in cancer. Low-molecular weight heparins are recommended for prolonged treatment (3-6 months or more if the cancer is active) and prevention of recurrence of venous thromboembolism in cancer. Community pharmacists are often faced with questions from patients. The main objective of this study was to describe the organization, practices and knowledge of pharmacists in care of venous thromboembolism in cancerpatients. METHODS: A descriptive survey was conducted electronically in October and November 2013 with pharmacists in the Champagne-Ardenne region. The questionnaire collected data on the general organization of the pharmacy, management of outpatients with cancer and thrombosis, and the level of knowledge regarding recommendations on the management of thrombosis in patients with cancer. RESULTS: The participation rate was 31.6%. In 93% of cases, pharmacists had no particular expertise in oncology and/or supportive care. In addition, 96% did not know the existence of recommendations for "thrombosis in cancer." Finally, 49% gave the correct answer to the case report (low-molecular weight heparins). CONCLUSION: Training sessions on the management of venous thromboembolism in cancer are currently available to pharmacists in the region. A new assessment of knowledge will be performed at the end of the year 2014. This regional experience is now extended to a national level (all French regions).